

PHYSICIAN/PHARMACIST ASSESSMENT FOR EZOGABINE REMS SURVEY (2013)

Note: The correct answers are highlighted in bold.

- 1) According to U.S. prescribing information, what is the FDA-approved indication for POTIGA? (Please select all that apply)

ALLOW MULTIPLE RESPONSES, EXCEPT 4 OR 5.

Migraine	1
Partial-onset seizures	2
Generalized tonic clonic seizures	3
None of the above	4
I don't know	5

- 2) True or False: According to U.S. prescribing information, POTIGA can be used as monotherapy.

ALLOW ONE RESPONSE.

True	1
False	2
I don't know	3

- 3) According to U.S. prescribing information, which of the following are potential risks associated with POTIGA? (Please select all that apply)

ALLOW MULTIPLE RESPONSES, EXCEPT PUNCH 4.

Urinary retention	1
Pancreatitis	2
Ischemic colitis	3
I don't know	4

- 4) According to U.S. prescribing information, what is the maximum recommended daily maintenance dose of POTIGA for the General Population?

ALLOW MULTIPLE RESPONSES, EXCEPT PUNCH 5 OR 6.

600mg	1
900mg	2
1200mg	3
2000mg	4
None of the above	5
I don't know	6

- 5) According to U.S. prescribing information, which of the following statements, if any, is true? (Please select all that apply)

ALLOW MULTIPLE RESPONSES, EXCEPT PUNCH 5 OR 6.

The oldest age at which POTIGA can be used is 65	1
There are no lower age limits for POTIGA	2
The youngest age at which POTIGA can be used is 12	3
The youngest age at which POTIGA can be used is 18	4
None of the above	5
I don't know	6

- 6) According to U.S. prescribing information, which of the following statements, if any, is true? (Please select all that apply)

ALLOW MULTIPLE RESPONSES, EXCEPT PUNCH 4 OR 5.

POTIGA should always be taken with food	1
POTIGA should always be taken on its own, without food	2
POTIGA can be taken with or without food	3
None of the above	4
I don't know	5

- 7) Which of the following urinary symptoms, if any, should you specifically advise patients taking POTIGA to watch out for? (Please select all that apply)

ALLOW MULTIPLE RESPONSES, EXCEPT PUNCH 5 OR 6.

Pain when urinating	1
Difficulty starting urination	2
Renal colic	3
Inability to urinate	4
None of the above	5
I don't know	6

- 8) If a patient on POTIGA experiences inability to pass urine, what would you advise them to do? (Please select all that apply)

ALLOW MULTIPLE RESPONSES, EXCEPT PUNCH 5 OR 6.

Report the issue at their next doctor's appointment	1
Drink more water	2
Seek immediate medical attention	3
Stop taking POTIGA	4
None of the above	5
I don't know	6

- 9) According to U.S. prescribing information, when increasing the dose, what is the maximum total daily dose at which POTIGA can be increased once every 7 days?

ALLOW MULTIPLE RESPONSES, EXCEPT PUNCH 5 OR 6.

Total daily dose increased by 50mg/day	1
Total daily dose increased by 150mg/day	2
Total daily dose increased by 200mg/day	3
Total daily dose increased by 300mg/day	4
None of the above	5
I don't know	6

- 10) True or False: According to U.S. prescribing information, for the General Population, the recommended total initial dosage should be 150mg per day for one week.

ALLOW ONE RESPONSE.

True	1
False	2
I don't know	3

11) The label for POTIGA recommends caution when prescribing for patients with which of the following conditions, if any?

		Yes	No	Don't Know
A	Moderate to severe renal or hepatic impairment	1	2	3
B	Moderate to severe Crohn's disease	1	2	3
C	Moderate to severe asthma	1	2	3
D	Patients over the age of 65 years	1	2	3
E	Moderate to severe glaucoma	1	2	3

12) True or False: It is known from controlled studies that adverse events related to voiding dysfunction generally tend to be reported within the first 6 months after starting POTIGA.

ALLOW ONE RESPONSE.

True	1
False	2
I don't know	3

13) Which of the following patient groups are recommended to have closer monitoring (including comprehensive evaluation of urologic symptoms) for urinary retention? (Please select all that apply)

ALLOW MULTIPLE RESPONSES, EXCEPT PUNCH 6 OR 7.

Patients with benign prostatic hyperplasia (BPH)	1
Patients who are unable to communicate clinical symptoms (e.g. cognitively impaired patients)	2
Patients who use concomitant medications that may affect voiding (e.g. anti-cholinergics)	3
Patients who use non-steroidal anti-inflammatory drugs (NSAIDs)	4
Patients who are obese	5
None of the above	6
I don't know	7

DEMOGRAPHICS (A) for Prescribers. SKIP TO DEMOGRAPHICS (B) IF PHARMACIST.

14) How long have you been practicing medicine?

ALLOW ONE RESPONSE.

Less than 5 years	1
5-15 years	2
16-25 years	3
26-35 years	4
More than 35 years	5

15) How long have you been prescribing anti-epileptic drugs (AEDs)?

ALLOW ONE RESPONSE.

Less than 5 years	1
5-15 years	2
16-25 years	3
26-35 years	4
More than 35 years	5

16) How many months have you been prescribing POTIGA?

ALLOW ONE RESPONSE.

Less than 1	1
1-3	2
4-6	3
7-9	4
10-12	5
More than 12 months	6
I don't know/don't remember	7

17) Approximately how many patients have you prescribed POTIGA for in the past 12 months?

ALLOW ONE RESPONSE.

1-2	1
3-10	2
11-20	3
More than 20 patients	4

18) Over the past year, approximately how many prescriptions for AEDs (including new prescriptions and refills) have you written per month on average?

ALLOW ONE RESPONSE.

1–10	1
11–30	2
31–50	3
More than 50	4

19) What is the age range of your current patient population? Please select all categories that you treat.

ALLOW MULTIPLE RESPONSES.

Pediatric (Under 18)	1
18-34	2
35-64	3
65 +	4

20) Approximately what is the size of your current total patient population?

ALLOW ONE RESPONSE.

Less than 100 patients	1
100 – 500 patients	2
501 – 1000 patients	3
More than 1000 patients	4

21) Approximately what is the size of your current epilepsy patient population?

ALLOW ONE RESPONSE.

Less than 10 patients	1
10 – 50 patients	2
51 – 100 patients	3
101+ patients	4
I do not treat patients with epilepsy	5

SKIP TO SECTION C IF PRESCRIBER.

DEMOGRAPHICS (B) for Pharmacists

22) How long have you been a practicing pharmacist?

ALLOW ONE RESPONSE.

Less than 5 years	1
5-15 years	2
16-25 years	3
26-35 years	4
More than 35 years	5

23) How long have you been dispensing and/or answering patient questions regarding prescribed AEDs?

ALLOW ONE RESPONSE.

Less than 5 years	1
5-15 years	2
16-25 years	3
26-35 years	4
More than 35 years	5

24) Have you answered any patient questions related to POTIGA in the past 12 months?

ALLOW ONE RESPONSE.

Yes	1
No	2
I don't know/don't remember	3

25) Have you dispensed POTIGA in the past 12 months?

ALLOW ONE RESPONSE.

Yes	1
No	2
I don't know/don't remember	3

IF Q25 IS NO OR DK/DR, SKIP TO Q28.

26) How many months have you been dispensing POTIGA?

ALLOW ONE RESPONSE.

Less than 1	1
1-3	2
4-6	3
7-9	4
10-12	5
More than 12 months	6
I don't know/don't remember	7

27) Approximately how many patients have you dispensed POTIGA for in the past 12 months?

ALLOW ONE RESPONSE.

1-2	1
3-10	2
11-20	3
More than 20 patients	4
I don't know/don't remember	5

28) Over the past year, approximately how many prescriptions for anti-epileptic drugs (AEDs) (including new prescriptions and refills) have you filled per month on average?

ALLOW ONE RESPONSE.

1 – 10	1
11 – 30	2
31 – 50	3
More than 50 prescriptions	4

SECTION C: The remaining questions are about your own personal experience, specifically regarding your awareness, receipt and dissemination of information about POTIGA.

29) Have you learned about the risks associated with the use of POTIGA from any of the following sources? **RANDOMIZE LIST.**

	Yes	No	Don't Know
POTIGA Dear HCP Letter	1	2	3
GlaxoSmithKline Medical Information	1	2	3
Other Healthcare Professionals	1	2	3
GlaxoSmithKline Promotional Materials	1	2	3
GSK Website: POTIGA.com	1	2	3
GlaxoSmithKline Sales Representatives	1	2	3
GlaxoSmithKline-sponsored Educational Meeting	1	2	3
POTIGA Product Labeling (including Prescribing Information, Medication Guide)	1	2	3

30) How would you prefer to learn about the risks associated with the use of POTIGA in the future? Please select up to 3 options. **RANDOMIZE LIST.**

POTIGA Dear HCP Letter	
GlaxoSmithKline Medical Information	
Other Healthcare Professionals	
GlaxoSmithKline Promotional Materials	
GSK Website: POTIGA.com	
GlaxoSmithKline Sales Representatives	
GlaxoSmithKline-sponsored Educational Meeting	
POTIGA Product Labeling (including Prescribing Information, Medication Guide)	